The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Renin-Angiotensin-System (RAS)-Acting Agents Market In 2026 And How Much Will It Reach By 2030?
Recent years have seen robust growth in the renin-angiotensin-system (ras)-acting agents market size. It is projected to expand from $6.11 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The expansion historically can be ascribed to high hypertension prevalence, aging population growth, widespread ACE inhibitor adoption, increased cardiovascular screening, and the affordability of generic drugs.
The renin-angiotensin-system (ras)-acting agents market size is projected to experience robust expansion over the coming years. This market is set to reach $7.96 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is primarily driven by factors such as the prevalence of chronic kidney disease, increasing demand for cardiometabolic medications, enhanced patient adherence to treatments, market expansion into developing regions, and the approval of combination therapies. Key trends influencing the market in this period encompass a rise in the adoption of combination antihypertensive therapies, the development of long-acting cardiovascular drugs, a heightened emphasis on renal protection treatments, the broader production of generic RAS drugs, and a move towards fixed-dose combination formulations.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
What Primary Factors Are Fueling The Expansion Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?
The increasing prevalence of hypertension is expected to propel the growth of the renin-angiotensin system (RAS)-acting agents market going forward. Hypertension, also known as high blood pressure, is a chronic medical condition characterized by persistently excessive force of blood against artery walls. This rise in hypertension prevalence is attributed to unhealthy diets, especially those high in salt and processed foods, which contribute to elevated blood pressure and strain on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents work to lower hypertension rates by regulating blood pressure. They do this by inhibiting angiotensin II, a hormone that constricts blood vessels and promotes fluid retention, thereby encouraging vasodilation and reducing blood pressure. For instance, in September 2025, the World Health Organization, a Switzerland-based intergovernmental organization, estimated that 1.4 billion adults worldwide aged 30–79 were living with hypertension in 2024, constituting about 33% of individuals in this age group. Therefore, the increasing prevalence of hypertension is driving the growth of the renin-angiotensin system (RAS)-acting agents market.
Which Segment Divisions Form The Structure Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?
The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
What Trends Are Affecting The Growth Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?
Leading firms within the renin-angiotensin system (RAS)-acting agents sector are concentrating on creating innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors. This development aims to boost effectiveness, reduce adverse reactions, increase patient adherence, and address conditions such as high blood pressure, cardiac insufficiency, and renal disorders. An angiotensin-converting enzyme (ACE) inhibitor functions as a drug designed to lower blood pressure by inhibiting the enzyme responsible for transforming angiotensin I into angiotensin II, a compound known to constrict blood vessels. As an illustration, in November 2023, Proveca Ltd., a pharmaceutical company based in the UK, was awarded a grant by the European Commission. This grant was for pediatric use marketing authorization (PUMA) for its Aqumeldi (enalapril maleate) orodispersible tablets, prescribed for managing heart failure in children from birth up to 18 years of age. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, addresses pediatric heart failure by inhibiting the angiotensin-converting enzyme (ACE). This action prevents the transformation of angiotensin I into angiotensin II, leading to blood vessel relaxation, enhanced blood circulation, and a reduced strain on the heart.
Who Are The Leading Firms Participating In The Renin-Angiotensin-System (RAS)-Acting Agents Market?
Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited
Access The Complete Renin-Angiotensin-System (RAS)-Acting Agents Market Report:
Which Regional Market Leads The Renin-Angiotensin-System (RAS)-Acting Agents Market?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Renin-Angiotensin-System (RAS)-Acting Agents Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2026, By The Business Research Company
Angiotensin Receptor Blockers Arbs Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Inotropic Agents Market Report 2026
https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model